These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7570674)

  • 21. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
    Marino DJ; Starr TB
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologically motivated quantitative models and the mixture toxicity problem.
    Conolly RB
    Toxicol Sci; 2001 Sep; 63(1):1-2. PubMed ID: 11509736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental and mathematical modeling methods for the investigation of toxicological interactions.
    El-Masri HA
    Toxicol Appl Pharmacol; 2007 Sep; 223(2):148-54. PubMed ID: 16996550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Policies for chemical hazard and risk priority setting: can persistence, bioaccumulation, toxicity, and quantity information be combined?
    Arnot JA; Mackay D
    Environ Sci Technol; 2008 Jul; 42(13):4648-54. PubMed ID: 18677986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites.
    Fisher JW
    Environ Health Perspect; 2000 May; 108 Suppl 2(Suppl 2):265-73. PubMed ID: 10807557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational pharmacokinetics during developmental windows of susceptibility.
    Barton HA
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):889-900. PubMed ID: 16020183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA
    Toxicol Lett; 1995 Dec; 82-83():497-504. PubMed ID: 8597101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches.
    Jarabek AM
    Toxicol Lett; 1995 Sep; 79(1-3):171-84. PubMed ID: 7570654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment.
    Tan YM; Clewell H; Campbell J; Andersen M
    Int J Environ Res Public Health; 2011 May; 8(5):1613-30. PubMed ID: 21655141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on "Steady State Solutions to PBPK Models and Their Applications to Risk Assessment I: Route to Route Extrapolation of Volatile Chemicals," by Chiu and White in Risk Analysis, 26(3), 769-780.
    Bogen KT
    Risk Anal; 2006 Dec; 26(6):1415; author reply 1417-8. PubMed ID: 17184387
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of mechanistic and pharmacokinetic data for risk assessment at the National Institute of Environmental Health Sciences (NIEHS).
    Schwetz BA
    Toxicol Lett; 1995 Sep; 79(1-3):29-32. PubMed ID: 7570667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.
    Tan YM; Worley RR; Leonard JA; Fisher JW
    Toxicol Sci; 2018 Apr; 162(2):341-348. PubMed ID: 29385573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment factors--applications in health risk assessment of chemicals.
    Falk-Filipsson A; Hanberg A; Victorin K; Warholm M; Wallén M
    Environ Res; 2007 May; 104(1):108-27. PubMed ID: 17166493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report.
    Bruckner JV
    Regul Toxicol Pharmacol; 2000 Jun; 31(3):280-5. PubMed ID: 10915586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicological consequences of multiple chemical interactions: a primer.
    Calabrese EJ
    Toxicology; 1995 Dec; 105(2-3):121-35. PubMed ID: 8571351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.